Abstract:Background: The discovery of anticancer drug combinations is a crucial work of anticancer treatment. In recent years, pre-screening drug combinations with synergistic effects in a large-scale search space adopting computational methods, especially deep learning methods, is increasingly popular with researchers. Although achievements have been made to predict anticancer synergistic drug combinations based on deep learning, the application of multi-task learning in this field is relatively rare. The successful practice of multi-task learning in various fields shows that it can effectively learn multiple tasks jointly and improve the performance of all the tasks. Methods: In this paper, we propose MTLSynergy which is based on multi-task learning and deep neural networks to predict synergistic anticancer drug combinations. It simultaneously learns two crucial prediction tasks in anticancer treatment, which are synergy prediction of drug combinations and sensitivity prediction of monotherapy. And MTLSynergy integrates the classification and regression of prediction tasks into the same model. Moreover, autoencoders are employed to reduce the dimensions of input features. Results: Compared with the previous methods listed in this paper, MTLSynergy achieves the lowest mean square error of 216.47 and the highest Pearson correlation coefficient of 0.76 on the drug synergy prediction task. On the corresponding classification task, the area under the receiver operator characteristics curve and the area under the precision-recall curve are 0.90 and 0.62, respectively, which are equivalent to the comparison methods. Through the ablation study, we verify that multi-task learning and autoencoder both have a positive effect on prediction performance. In addition, the prediction results of MTLSynergy in many cases are also consistent with previous studies. Conclusion: Our study suggests that multi-task learning is significantly beneficial for both drug synergy prediction and monotherapy sensitivity prediction when combining these two tasks into one model. The ability of MTLSynergy to discover new anticancer synergistic drug combinations noteworthily outperforms other state-of-the-art methods. MTLSynergy promises to be a powerful tool to pre-screen anticancer synergistic drug combinations.

Fusing Micro- and Macro-Scale Information to Predict Anticancer Synergistic Drug Combinations

MMFSyn: A Multimodal Deep Learning Model for Predicting Anticancer Synergistic Drug Combination Effect

Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies

Synergistic Drug Combination Prediction by Integrating Multi-omics Data in Deep Learning Models

Predicting anticancer synergistic drug combinations based on multi-task learning

A granularity-level information fusion strategy on hypergraph transformer for predicting synergistic effects of anticancer drugs

MMSyn: A New Multimodal Deep Learning Framework for Enhanced Prediction of Synergistic Drug Combinations

GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction

Trustworthy Deep Neural Network for Inferring Anticancer Synergistic Combinations

Multi-way relation-enhanced hypergraph representation learning for anti-cancer drug synergy prediction

CFSSynergy: Combining Feature-Based and Similarity-Based Methods for Drug Synergy Prediction

MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction

CCSynergy: an integrative deep-learning framework enabling context-aware prediction of anti-cancer drug synergy

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

A Deep Neural Network for Predicting Synergistic Drug Combinations on Cancer

Prediction of Synergistic Anti-Cancer Drug Combinations Based on Drug Target Network and Drug Induced Gene Expression Profiles

Predicting drug synergy using a network propagation inspired machine learning framework

Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer

DeepSynergy: predicting anti-cancer drug synergy with Deep Learning

Prediction of anti-cancer drug synergy based on cross-matching network and cancer molecular subtypes

[SMILESynergy: Anticancer drug synergy prediction based on Transformer pre-trained model].